February 20, 2023Open Access

Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Our findings reveal that SLC25A47, a hepatocyte-specific mitochondrial NAD + transporter, is one of the pharmacological targets of metformin and regulates lipid homeostasis through AMPKα, and may serve as a potential drug target for treating NAFLD and HCC.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Cheng et al. (Mon,) studied this question.

synapsesocial.com/papers/69da7dad0d540cafc5839221 https://doi.org/https://doi.org/10.1097/hep.0000000000000314

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin2014 · 237 citations
2The SLC transporter in nutrient and metabolic sensing, regulation, and drug development2018 · 232 citations
3Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus2021 · 494 citations
4mTORC1 signaling in hepatic lipid metabolism2017 · 168 citations
5A functional mammalian target of rapamycin complex 1 signaling is indispensable for c‐Myc‐driven hepatocarcinogenesis2017 · 196 citations

Me gusta

Guardar

Ver artículo completo